Heidi A. Lane, Ed.D. - Publications

Affiliations: 
2005 East Carolina University, Greenville, NC, United States 
Area:
Higher Education, Education

76 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2021 Burgenske DM, Talele S, Pokorny JL, Mladek AC, Bakken KK, Carlson BL, Schroeder MA, He L, Hu Z, Gampa G, Kosel ML, Decker PA, Kitange GJ, Schmitt-Hoffmann A, Bachmann F, ... ... Lane HA, et al. Preclinical modeling in GBM PDX xenografts to guide clinical development of lisavanbulin - a novel tumor checkpoint controller targeting microtubules. Neuro-Oncology. PMID 34232318 DOI: 10.1093/neuonc/noab162  0.01
2020 Kristeleit R, Evans J, Molife LR, Tunariu N, Shaw H, Slater S, Haris NRM, Brown NF, Forster MD, Diamantis N, Rulach R, Greystoke A, Asghar U, Rata M, Anderson S, ... ... Lane HA, et al. Phase 1/2a trial of intravenous BAL101553, a novel controller of the spindle assembly checkpoint, in advanced solid tumours. British Journal of Cancer. PMID 32741975 DOI: 10.1038/s41416-020-1010-8  0.01
2020 Bergès R, Tchoghandjian A, Sergé A, Honoré S, Figarella-Branger D, Bachmann F, Lane HA, Braguer D. EB1-dependent long survival of glioblastoma-grafted mice with the oral tubulin-binder BAL101553 is associated with inhibition of tumor angiogenesis. Oncotarget. 11: 759-774. PMID 32165998 DOI: 10.18632/Oncotarget.27374  0.01
2018 Benjamin D, Robay D, Hindupur SK, Pohlmann J, Colombi M, El-Shemerly MY, Maira SM, Moroni C, Lane HA, Hall MN. Dual Inhibition of the Lactate Transporters MCT1 and MCT4 Is Synthetic Lethal with Metformin due to NAD+ Depletion in Cancer Cells. Cell Reports. 25: 3047-3058.e4. PMID 30540938 DOI: 10.1016/j.celrep.2018.11.043  0.01
2017 Sharma A, Broggini-Tenzer A, Vuong V, Messikommer A, Nytko KJ, Guckenberger M, Bachmann F, Lane HA, Pruschy M. The novel microtubule targeting agent BAL101553 in combination with radiotherapy in treatment-refractory tumor models. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. PMID 28797699 DOI: 10.1016/j.radonc.2017.07.024  0.01
2016 Benjamin D, Colombi M, Hindupur SK, Betz C, Lane HA, El-Shemerly MY, Lu M, Quagliata L, Terracciano L, Moes S, Sharpe T, Wodnar-Filipowicz A, Moroni C, Hall MN. Syrosingopine sensitizes cancer cells to killing by metformin. Science Advances. 2: e1601756. PMID 28028542 DOI: 10.1126/sciadv.1601756  0.01
2016 Berges R, Tchoghandjian A, Honore S, Esteve MA, Figarella-Branger D, Bachmann F, Lane HA, Braguer D. The novel tubulin-binding, checkpoint activator BAL101553 inhibits EB1-dependent migration and invasion and promotes differentiation of glioblastoma stem-like cells. Molecular Cancer Therapeutics. PMID 27540016 DOI: 10.1158/1535-7163.Mct-16-0252  0.01
2013 Lombardi SA, Chon GD, Lee JJ, Lane HA, Paynter KT. Shell hardness and compressive strength of the Eastern oyster, Crassostrea virginica, and the Asian oyster, Crassostrea ariakensis. The Biological Bulletin. 225: 175-83. PMID 24445443 DOI: 10.1086/Bblv225N3P175  1
2012 Martin LA, Pancholi S, Farmer I, Guest S, Ribas R, Weigel MT, Thornhill AM, Ghazoui Z, A'Hern R, Evans DB, Lane HA, Johnston SR, Dowsett M. Effectiveness and molecular interactions of the clinically active mTORC1 inhibitor everolimus in combination with tamoxifen or letrozole in vitro and in vivo. Breast Cancer Research : Bcr. 14: R132. PMID 23075476 DOI: 10.1186/bcr3330  1
2012 Bashore CJ, Lane HA, Paynter KT, Naylor M, Harding JR, Love DC. Analysis of marine police citations and judicial decisions for illegal harvesting of eastern oysters (Crassostrea Virginica, Gmelin 1791) in the maryland portion of the chesapeake bay, United States, from 1959 to 2010 Journal of Shellfish Research. 31: 591-598. DOI: 10.2983/035.031.0301  1
2011 Lebwohl D, Thomas G, Lane HA, O'Reilly T, Escudier B, Yao JC, Pavel M, Franz D, Berg W, Baladi JF, Stewart J, Motzer RJ. Research and innovation in the development of everolimus for oncology. Expert Opinion On Drug Discovery. 6: 323-38. PMID 22647206 DOI: 10.1517/17460441.2011.558079  1
2011 O'Reilly T, McSheehy PM, Wartmann M, Lassota P, Brandt R, Lane HA. Evaluation of the mTOR inhibitor, everolimus, in combination with cytotoxic antitumor agents using human tumor models in vitro and in vivo. Anti-Cancer Drugs. 22: 58-78. PMID 20890178 DOI: 10.1097/CAD.0b013e3283400a20  1
2011 O'Reilly T, Lane HA, Wood JM, Schnell C, Littlewood-Evans A, Brueggen J, McSheehy PM. Everolimus and PTK/ZK show synergistic growth inhibition in the orthotopic BL16/BL6 murine melanoma model. Cancer Chemotherapy and Pharmacology. 67: 193-200. PMID 20512579 DOI: 10.1007/s00280-010-1307-z  1
2011 Kulp RE, Politano V, Lane HA, Lombardi SA, Paynter KT. Predation of juvenile Crassostrea virginica by two species of mud crabs found in the Chesapeake Bay Journal of Shellfish Research. 30: 261-266. DOI: 10.2983/035.030.0210  1
2011 Lane HA, Westgate AJ, Koopman HN. Ontogenetic and temporal variability in the fat content and fatty acid composition of Atlantic herring (Clupea harengus) from the Bay of Fundy, Canada Fishery Bulletin. 109: 113-122.  1
2010 Honer M, Ebenhan T, Allegrini PR, Ametamey SM, Becquet M, Cannet C, Lane HA, O'Reilly TM, Schubiger PA, Sticker-Jantscheff M, Stumm M, McSheehy PM. Anti-Angiogenic/Vascular Effects of the mTOR Inhibitor Everolimus Are Not Detectable by FDG/FLT-PET. Translational Oncology. 3: 264-75. PMID 20689768  0.01
2010 O'Reilly T, McSheehy PM, Kawai R, Kretz O, McMahon L, Brueggen J, Bruelisauer A, Gschwind HP, Allegrini PR, Lane HA. Comparative pharmacokinetics of RAD001 (everolimus) in normal and tumor-bearing rodents. Cancer Chemotherapy and Pharmacology. 65: 625-39. PMID 19784839 DOI: 10.1007/s00280-009-1068-8  1
2010 Paynter KT, Politano V, Lane HA, Allen SM, Meritt D. Growth rates and prevalence of perkinsus marinus in restored oyster populations in Maryland Journal of Shellfish Research. 29: 309-317. DOI: 10.2983/035.029.0205  1
2010 Honer M, Ebenhan T, Allegrini PR, Ametamey SM, Becquet M, Cannet C, Lane HA, O'Reilly TM, Schubiger PA, Sticker-Jantscheff M, Stumm M, McSheehy PMJ. Anti-angiogenic/vascular effects of the mTOR inhibitor everolimus are not detectable by FDG/FLT-PET Translational Oncology. 3: 264-275. DOI: 10.1593/tlo.10127  1
2010 Ronconi RA, Swaim ZT, Lane HA, Hunnewell RW, Westgate AJ, Koopman HN. Modified hoop-net techniques for capturing birds at sea and comparison with other capture methods Marine Ornithology. 38: 23-29.  1
2009 Baselga J, Semiglazov V, van Dam P, Manikhas A, Bellet M, Mayordomo J, Campone M, Kubista E, Greil R, Bianchi G, Steinseifer J, Molloy B, Tokaji E, Gardner H, Phillips P, ... Lane HA, et al. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 2630-7. PMID 19380449 DOI: 10.1200/JCO.2008.18.8391  1
2009 Breuleux M, Klopfenstein M, Stephan C, Doughty CA, Barys L, Maira SM, Kwiatkowski D, Lane HA. Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K/mTOR inhibition. Molecular Cancer Therapeutics. 8: 742-53. PMID 19372546 DOI: 10.1158/1535-7163.MCT-08-0668  1
2009 Lane HA, Breuleux M. Optimal targeting of the mTORC1 kinase in human cancer. Current Opinion in Cell Biology. 21: 219-29. PMID 19233631 DOI: 10.1016/j.ceb.2009.01.016  1
2009 Marinov M, Ziogas A, Pardo OE, Tan LT, Dhillon T, Mauri FA, Lane HA, Lemoine NR, Zangemeister-Wittke U, Seckl MJ, Arcaro A. AKT/mTOR pathway activation and BCL-2 family proteins modulate the sensitivity of human small cell lung cancer cells to RAD001. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 1277-87. PMID 19228731 DOI: 10.1158/1078-0432.CCR-08-2166  1
2009 Lane HA, Wood JM, McSheehy PM, Allegrini PR, Boulay A, Brueggen J, Littlewood-Evans A, Maira SM, Martiny-Baron G, Schnell CR, Sini P, O'Reilly T. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 1612-22. PMID 19223496 DOI: 10.1158/1078-0432.CCR-08-2057  1
2008 Fujishita T, Aoki K, Lane HA, Aoki M, Taketo MM. Inhibition of the mTORC1 pathway suppresses intestinal polyp formation and reduces mortality in ApcDelta716 mice. Proceedings of the National Academy of Sciences of the United States of America. 105: 13544-9. PMID 18768809 DOI: 10.1073/pnas.0800041105  1
2008 Yang L, Clarke MJ, Carlson BL, Mladek AC, Schroeder MA, Decker P, Wu W, Kitange GJ, Grogan PT, Goble JM, Uhm J, Galanis E, Giannini C, Lane HA, James CD, et al. PTEN loss does not predict for response to RAD001 (Everolimus) in a glioblastoma orthotopic xenograft test panel. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 3993-4001. PMID 18559622 DOI: 10.1158/1078-0432.CCR-07-4152  1
2008 Croyle M, Akeno N, Knauf JA, Fabbro D, Chen X, Baumgartner JE, Lane HA, Fagin JA. RET/PTC-induced cell growth is mediated in part by epidermal growth factor receptor (EGFR) activation: evidence for molecular and functional interactions between RET and EGFR. Cancer Research. 68: 4183-91. PMID 18519677 DOI: 10.1158/0008-5472.Can-08-0413  1
2008 Johansson G, Mahller YY, Collins MH, Kim MO, Nobukuni T, Perentesis J, Cripe TP, Lane HA, Kozma SC, Thomas G, Ratner N. Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors. Molecular Cancer Therapeutics. 7: 1237-45. PMID 18483311 DOI: 10.1158/1535-7163.Mct-07-2335  1
2008 Boulay A, Breuleux M, Stephan C, Fux C, Brisken C, Fiche M, Wartmann M, Stumm M, Lane HA, Hynes NE. The Ret receptor tyrosine kinase pathway functionally interacts with the ERalpha pathway in breast cancer. Cancer Research. 68: 3743-51. PMID 18483257 DOI: 10.1158/0008-5472.CAN-07-5100  1
2008 O'Donnell A, Faivre S, Burris HA, Rea D, Papadimitrakopoulou V, Shand N, Lane HA, Hazell K, Zoellner U, Kovarik JM, Brock C, Jones S, Raymond E, Judson I. Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 1588-95. PMID 18332470 DOI: 10.1200/JCO.2007.14.0988  1
2008 Tabernero J, Rojo F, Calvo E, Burris H, Judson I, Hazell K, Martinelli E, Ramon y Cajal S, Jones S, Vidal L, Shand N, Macarulla T, Ramos FJ, Dimitrijevic S, Zoellner U, ... Lane HA, et al. Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 1603-10. PMID 18332469 DOI: 10.1200/JCO.2007.14.5482  1
2008 Tanaka C, O'Reilly T, Kovarik JM, Shand N, Hazell K, Judson I, Raymond E, Zumstein-Mecker S, Stephan C, Boulay A, Hattenberger M, Thomas G, Lane HA. Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 1596-602. PMID 18332467 DOI: 10.1200/JCO.2007.14.1127  1
2007 Akeno-Stuart N, Croyle M, Knauf JA, Malaguarnera R, Vitagliano D, Santoro M, Stephan C, Grosios K, Wartmann M, Cozens R, Caravatti G, Fabbro D, Lane HA, Fagin JA. The RET kinase inhibitor NVP-AST487 blocks growth and calcitonin gene expression through distinct mechanisms in medullary thyroid cancer cells. Cancer Research. 67: 6956-64. PMID 17638907 DOI: 10.1158/0008-5472.Can-06-4605  1
2007 Boulay A, Lane HA. The mammalian target of rapamycin kinase and tumor growth inhibition. Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progrã¨S Dans Les Recherches Sur Le Cancer. 172: 99-124. PMID 17607938  1
2006 Lane HA, Smith JC, Davies JS. Noninvasive assessment of preclinical atherosclerosis. Vascular Health and Risk Management. 2: 19-30. PMID 17319466 DOI: 10.2147/vhrm.2006.2.1.19  1
2006 Lane HA, Grace F, Smith JC, Morris K, Cockcroft J, Scanlon MF, Davies JS. Impaired vasoreactivity in bodybuilders using androgenic anabolic steroids. European Journal of Clinical Investigation. 36: 483-8. PMID 16796605 DOI: 10.1111/j.1365-2362.2006.01667.x  1
2006 Lane HA, Lebwohl D. Future directions in the treatment of hormone-sensitive advanced breast cancer: the RAD001 (Everolimus)-letrozole clinical program. Seminars in Oncology. 33: S18-25. PMID 16730273 DOI: 10.1053/j.seminoncol.2006.03.024  1
2005 Boulay A, Rudloff J, Ye J, Zumstein-Mecker S, O'Reilly T, Evans DB, Chen S, Lane HA. Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 5319-28. PMID 16033851 DOI: 10.1158/1078-0432.CCR-04-2402  1
2005 Spanggord HM, Epstein RJ, Lane HA, Candal EM, Klein SR, Majmudar PA, Dennis RF. Flap suturing with proparacaine for recurrent epithelial ingrowth following laser in situ keratomileusis surgery. Journal of Cataract and Refractive Surgery. 31: 916-21. PMID 15975456 DOI: 10.1016/j.jcrs.2004.12.042  1
2005 Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nature Reviews. Cancer. 5: 341-54. PMID 15864276 DOI: 10.1038/nrc1609  1
2005 Beuvink I, Boulay A, Fumagalli S, Zilbermann F, Ruetz S, O'Reilly T, Natt F, Hall J, Lane HA, Thomas G. The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell. 120: 747-59. PMID 15797377 DOI: 10.1016/j.cell.2004.12.040  1
2005 Goudar RK, Shi Q, Hjelmeland MD, Keir ST, McLendon RE, Wikstrand CJ, Reese ED, Conrad CA, Traxler P, Lane HA, Reardon DA, Cavenee WK, Wang XF, Bigner DD, Friedman HS, et al. Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. Molecular Cancer Therapeutics. 4: 101-12. PMID 15657358  1
2004 Traxler P, Allegrini PR, Brandt R, Brueggen J, Cozens R, Fabbro D, Grosios K, Lane HA, McSheehy P, Mestan J, Meyer T, Tang C, Wartmann M, Wood J, Caravatti G. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity. Cancer Research. 64: 4931-41. PMID 15256466 DOI: 10.1158/0008-5472.Can-03-3681  1
2004 Majumder PK, Febbo PG, Bikoff R, Berger R, Xue Q, McMahon LM, Manola J, Brugarolas J, McDonnell TJ, Golub TR, Loda M, Lane HA, Sellers WR. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nature Medicine. 10: 594-601. PMID 15156201 DOI: 10.1038/Nm1052  1
2004 Boulay A, Zumstein-Mecker S, Stephan C, Beuvink I, Zilbermann F, Haller R, Tobler S, Heusser C, O'Reilly T, Stolz B, Marti A, Thomas G, Lane HA. Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells. Cancer Research. 64: 252-61. PMID 14729632 DOI: 10.1158/0008-5472.CAN-3554-2  1
2003 Smith JC, Lane HA, Lewis J, Dann S, Goodfellow J, Collins P, Evans LM, Scanlon MF, Davies JS. Endothelial function and coagulant factors in growth hormone-treated hypopituitary adults receiving desmopressin. The Journal of Clinical Endocrinology and Metabolism. 88: 2152-6. PMID 12727969 DOI: 10.1210/Jc.2002-021618  1
2003 Lane HA, Swale JA, Majmudar PA. Prophylactic use of mitomycin-C in the management of a buttonholed LASIK flap. Journal of Cataract and Refractive Surgery. 29: 390-2. PMID 12648655 DOI: 10.1016/S0886-3350(02)01434-7  1
2002 Motoyama AB, Hynes NE, Lane HA. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides. Cancer Research. 62: 3151-8. PMID 12036928  1
2001 Neve RM, Lane HA, Hynes NE. The role of overexpressed HER2 in transformation Annals of Oncology. 12: S9-S13. PMID 11521729  1
2001 Lane HA, Motoyama AB, Beuvink I, Hynes NE. Modulation of p27/Cdk2 complex formation through 4D5-mediated inhibition of HER2 receptor signaling Annals of Oncology. 12: S21-S22. PMID 11521716  1
2001 Hynes NE, Lane HA. Myc and Mammary Cancer: Myc is a Downstream Effector of the ErbB2 Receptor Tyrosine Kinase Journal of Mammary Gland Biology and Neoplasia. 6: 141-150. PMID 11467449 DOI: 10.1023/A:1009528918064  1
2000 Olayioye MA, Neve RM, Lane HA, Hynes NE. The ErbB signaling network: Receptor heterodimerization in development and cancer Embo Journal. 19: 3159-3167. PMID 10880430  1
2000 Neve RM, Sutterlüty H, Pullen N, Lane HA, Daly JM, Krek W, Hynes NE. Effects of oncogenic ErbB2 on G1 cell cycle regulators in breast tumour cells Oncogene. 19: 1647-1656. PMID 10763821 DOI: 10.1038/Sj.Onc.1203470  1
2000 Lane HA, Beuvink I, Motoyama AB, Daly JM, Neve RM, Hynes NE. ErbB2 potentiates breast tumor proliferation through modulation of p27(Kip1)-Cdk2 complex formation: Receptor overexpression does not determine growth dependency Molecular and Cellular Biology. 20: 3210-3223. PMID 10757805 DOI: 10.1128/MCB.20.9.3210-3223.2000  1
1999 Daly JM, Olayioye MA, Wong AM, Neve R, Lane HA, Maurer FG, Hynes NE. NDF/heregulin-induced cell cycle changes and apoptosis in breast tumour cells: role of PI3 kinase and p38 MAP kinase pathways. Oncogene. 18: 3440-51. PMID 10376522 DOI: 10.1038/sj.onc.1202700  1
1997 Mundt KE, Golsteyn RM, Lane HA, Nigg EA. On the regulation and function of human polo-like kinase 1 (PLK1): Effects of overexpression on cell cycle progression Biochemical and Biophysical Research Communications. 239: 377-385. PMID 9344838 DOI: 10.1006/Bbrc.1997.7378  1
1997 Lane HA, Nigg EA. Cell-cycle control: POLO-like kinases join the outer circle Trends in Cell Biology. 7: 63-68. DOI: 10.1016/S0962-8924(96)10051-9  1
1996 Golsteyn RM, Lane HA, Mundt KE, Arnaud L, Nigg EA. The family of polo-like kinases Progress in Cell Cycle Research. 2: 107-114. PMID 9552388 DOI: 10.1007/978-1-4615-5873-6_11  1
1996 Lane HA, Nigg EA. Antibody microinjection reveals an essential role for human polo-like kinase 1 (Plk1) in the functional maturation of mitotic centrosomes Journal of Cell Biology. 135: 1701-1713. PMID 8991084 DOI: 10.1083/Jcb.135.6.1701  1
1996 Nigg EA, Blangy A, Lane HA. Dynamic changes in nuclear architecture during mitosis: On the role of protein phosphorylation in spindle assembly and chromosome segregation Experimental Cell Research. 229: 174-180. PMID 8986594 DOI: 10.1006/Excr.1996.0356  1
1996 Lane HA, Baldwin RL, Dawaon TE. Dietary effects ok sheep rumen morphological development Faseb Journal. 10: A514.  1
1995 Blangy A, Lane HA, D'Hérin P, Harper M, Kress M, Nigg EA. Phosphorylation by p34cdc2 regulates spindle association of human Eg5, a kinesin-related motor essential for bipolar spindle formation in vivo Cell. 83: 1159-1169. PMID 8548803 DOI: 10.1016/0092-8674(95)90142-6  1
1993 Lane HA, Fernandez A, Lamb NJC, Thomas G. P70s6k function is essential for G1 progression Nature. 363: 170-172. PMID 8483501 DOI: 10.1038/363170A0  1
1992 Šuša M, Vulević D, Lane HA, Thomas G. Inhibition or down-regulation of protein kinase C attenuates late phase p70s6k activation induced by epidermal growth factor but not by platelet-derived growth factor or insulin Journal of Biological Chemistry. 267: 6905-6909. PMID 1551899  1
1992 Lane HA, Morley SJ, Dorée M, Kozma SC, Thomas G. Identification and early activation of a Xenopus laevis p70s6k following progesterone-induced meiotic maturation Embo Journal. 11: 1743-1749. PMID 1374712  1
1991 Lane HA, Thomas G. Purification and properties of mitogen-activated S6 kinase from rat liver and 3T3 cells Methods in Enzymology. 200: 268-291. PMID 1956322 DOI: 10.1016/0076-6879(91)00146-N  1
1989 Kozma SC, Lane HA, Ferrari S, Luther H, Siegmann M, Thomas G. A stimulated S6 kinase from rat liver: identity with the mitogen activated S6 kinase of 3T3 cells Embo Journal. 8: 4125-4132. PMID 2686982  1
1979 Lane HA, Ling JR. The in vitro metabolism of 2,6-diaminopimelic acid by rumen micro-organisms Proceedings of the Nutrition Society. 38: 80A. PMID 504199  1
1946 Lane HA. Legal and Medical “Insanity” British Medical Journal. 2: 668-669. DOI: 10.1136/bmj.2.4478.668-c  1
1940 Burnet J, Lane HA. What is Influenza? British Medical Journal. 1: 830. DOI: 10.1136/bmj.1.4141.830  1
1939 Lane HA. Importance of blood examination British Medical Journal. 2: 91. DOI: 10.1136/bmj.2.4096.91-b  1
1938 Lane HA. URINARY INFECTIONS AND THE BED-PAN The Lancet. 232: 1085-1086.  1
1937 Strang R, Lane HA, Lincoln EA. Chapter V: Health and Physical Education Review of Educational Research. 7: 482-490. DOI: 10.3102/00346543007005482  1
1934 Lane HA, Witty PA. The educational attainment of delinquent boys Journal of Educational Psychology. 25: 695-702. DOI: 10.1037/h0072948  1
1930 Lane HA. The tepid bath in the treatment of measles British Medical Journal. 1: 839. DOI: 10.1136/bmj.1.3617.839-a  1
Show low-probability matches.